Every Form 4 that Arteris, Inc. (AIP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AIP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIP filings page.
Arteris, Inc. (AIP) reported that K. Charles Janac, its President, CEO and a more than ten percent owner, had an affiliated entity sell 100,000 shares of Common Stock on September 1, 2026 at a weighted average price of $20.7497 per share in a sale transaction.
The shares were sold by Bayview Legacy, LLC, an entity for which Janac serves as manager and is deemed to have voting and dispositive power. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025. After the sales, Bayview Legacy, LLC held 8,229,071 shares indirectly, Janac held 175,148 shares directly, and the Charles and Lydia Janac Trust held 56,252 shares indirectly.
Arteris, Inc. (AIP) had a significant shareholder, Bayview Legacy, LLC, report the sale of 100,000 shares of Common Stock on September 1, 2026. The weighted average sale price was $20.7497 per share, with individual trades between $20.465 and $21.410.
After this transaction, Bayview Legacy, LLC reported 8,229,071 shares of Arteris Common Stock held indirectly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by K. Charles Janac, as manager of Bayview Legacy, LLC, on December 12, 2025, and Janac is deemed to have voting and dispositive power over these shares.
Arteris, Inc. (AIP) reported that its VP and General Counsel, Paul L. Alpern, exercised 4,000 incentive stock options for Arteris common stock on September 1, 2026 at an exercise price of $0.56 per share, receiving 4,000 common shares. On the same date, he sold 4,000 common shares at a weighted average price of $20.7658 per share in multiple trades between $20.61 and $21.38. Following the option exercise, he continues to hold 49,000 incentive stock options expiring on October 23, 2029. The acquisitions and sales were made pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026.
Arteris, Inc. (AIP) director Wayne C. Cantwell reported several transactions. On August 28, 2026, he exercised 5,000 non-qualified stock options at $0.60 per share to acquire 5,000 shares of common stock, leaving 70,000 options outstanding. On September 1, 2026, he made a bona fide gift of 5,000 directly held shares to The Cantwell Living Trust, for which he serves as trustee; the trust then held 194,698 shares. An additional 38,761 shares are held indirectly through a Decathlon Capital Management 401(k) plan for his benefit.
Arteris, Inc. VP and CFO Nicholas B. Hawkins reported an option exercise and share sales. On August 13, 2026 he exercised 3,125 Non-Qualified Stock Options at an exercise price of $9.28 per share, receiving 3,125 shares of common stock, and leaving 31,250 options outstanding from this grant. The options vest in 16 equal quarterly installments beginning April 1, 2025. On August 12–13, 2026 he sold a total of 10,631 shares of common stock in transactions at prices around $28.26–$29.00 per share, including a weighted average sale price of $28.2646, with all holdings reported as direct ownership.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open‑market sales totaling 100,000 shares of common stock on August 3–4, 2026. The five indirect transactions, executed under a Rule 10b5‑1 trading plan adopted on December 12, 2025, used weighted‑average pricing, with underlying trade ranges from $28.17 to $32.48 per share. K. Charles Janac, Bayview’s manager, is deemed to have voting and dispositive power over these shares and has separately reported his beneficial ownership.
Arteris, Inc. director Saiyed Atiq Raza, through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, sold a total of 70,000 common shares on August 3, 2026 in three open-market transactions at weighted average prices of $28.7765, $29.9898 and $30.3009 per share within stated price ranges. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025. A separate holding entry reports 4,703 common shares held directly.
Arteris, Inc. VP and General Counsel Paul L. Alpern exercised 4,000 incentive stock options at $0.56 per share on August 3, 2026, receiving 4,000 shares of common stock. The same day, he sold 600 and 3,400 shares at weighted-average prices of $29.11 and $30.1991 in transactions made pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026. Following the option exercise, 53,000 options from this grant remained outstanding.
Arteris, Inc. director, President and CEO K. Charles Janac reported indirect sales of 100,000 shares of common stock through Bayview Legacy, LLC on August 3–4, 2026. The shares were sold in multiple transactions at weighted-average prices of $28.7865, $29.9906, $30.3132, $31.9217 and $32.4149 per share under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following these sales, he reports 175,148 shares held directly and 56,252 shares held indirectly via the Charles and Lydia Janac Trust.
Arteris, Inc. director, President and CEO K. Charles Janac reported open-market sales of common stock mainly through indirect holdings. On July 6, 2026, entities associated with him sold an aggregate of 136,655 shares of Arteris common stock in several transactions.
The reported sales, including those by Bayview Legacy, LLC and direct holdings, occurred at weighted average prices between roughly $35 and $37 per share. According to the disclosure, these trades were executed under a Rule 10b5-1 trading plan adopted on December 12, 2025, and Janac continues to hold substantial direct and indirect positions, including shares in the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), reported open-market sales of a total of 125,976 shares of common stock on July 6, 2026. The sales were executed in three tranches at weighted average prices of $35.065, $36.2365, and $37.0705 per share.
The trades were made pursuant to a Rule 10b5-1 trading plan adopted by K. Charles Janac, the manager of Bayview Legacy, LLC, on December 12, 2025. Janac is deemed to have voting and dispositive power over the shares held by Bayview Legacy, and he has separately filed a Form 4 reflecting the same transactions.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported selling 6,003 shares of common stock in open-market transactions on July 6, 2026. The sales were executed at weighted average prices in ranges between $34.65 and $37.57 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 70,733 shares of Arteris common stock.
Kunkel Joachim reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Joachim Kunkel reported receiving a grant of 365 shares of common stock as fully vested restricted stock. These shares represent director retainer fees that he chose to take in stock instead of cash, at no cash cost per share. The grant was calculated using an average Arteris trading price of $39.28 over a defined period, and Kunkel elected to defer the actual receipt of the shares, leaving his reported direct holdings at 74,695 shares after the award.
Munce Claudia F. reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Claudia F. Munce received an award of 350 shares of common stock as fully vested restricted stock. According to the disclosure, this represents retainer fees she elected to take in stock instead of cash, valued using an average trading price of $39.28.
The grant was made on July 5, 2026 and brings her directly held position to 106,764 common shares. The filing also notes that she elected to defer the actual receipt of the shares, indicating this is structured as deferred equity compensation rather than an open-market purchase.
Arteris, Inc. director, President and CEO K. Charles Janac reported multiple sales of Arteris common stock on July 2, 2026. The Form 4 shows net sales of 203,588 shares at various weighted average prices between $34.20 and $43.51 per share.
According to the footnotes, a portion of the shares was sold to satisfy Mr. Janac’s tax liability from the release of restricted stock units under the company’s equity incentive plans, using mandatory “sell to cover” transactions rather than discretionary trades. Additional sales were made by Bayview Legacy, LLC under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025.
After these transactions, Mr. Janac continues to hold Arteris shares both directly and indirectly, including 56,252 shares held by the Charles and Lydia Janac Trust, 193,508 shares held directly, and 8,736,733 shares beneficially owned through Bayview Legacy, LLC.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of 192,686 shares of Arteris common stock. The trades occurred on July 2, 2026 across eight transactions at weighted average prices between $34.77 and $43.24 per share. The filing notes that these sales were made pursuant to a Rule 10b5-1 trading plan adopted by Bayview’s manager, K. Charles Janac, on December 12, 2025, indicating the transactions were pre-scheduled rather than opportunistic.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported tax-driven sales of common stock. On July 2, 2026, he sold a total of 5,599 shares of Arteris common stock in multiple open-market transactions at $38.7779 per share.
According to the footnote, these sales were executed solely to satisfy his tax liability from the release of restricted stock units under the company’s equity incentive plans. The transactions were mandated "sell to cover" trades and are described as non-discretionary for the reporting person.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported selling 3,648 shares of common stock on July 2, 2026 in four open-market transactions at a price of $38.7779 per share.
According to the filing, these sales were made to satisfy the reporting person's tax liability from the release of restricted stock units and were mandated under the company’s equity incentive plans as "sell to cover" transactions, meaning they were not discretionary trades.
Arteris, Inc. VP and CFO Nicholas B. Hawkins reported routine tax-related share sales. On July 2, 2026, he sold a total of 5,377 shares of Arteris common stock in multiple open-market transactions at $38.7779 per share.
According to the footnote, these transactions were mandated "sell to cover" sales to satisfy tax liabilities from the release of restricted stock units under the company’s equity incentive plans, and are described as non-discretionary. After these sales, Hawkins directly owned 103,172 shares of Arteris common stock.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported multiple transactions in the company’s common stock on July 1, 2026. He sold a total of 6,500 shares in open-market transactions at weighted average prices ranging from about $43.70 to $47.50, carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026. On the same date, he exercised stock options to acquire 6,500 shares of common stock at exercise prices of $9.28 and $0.56 per share. Following these transactions, he continues to hold more than 80,000 shares of Arteris common stock directly.
Arteris, Inc. director and CEO K. Charles Janac reported indirect open-market sales of 181,338 shares of Arteris common stock on July 1, 2026 through Bayview Legacy, LLC, where he serves as manager. The sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025, at weighted-average prices reported between $44.0606 and $47.0752 per share.
Following these transactions, Bayview Legacy, LLC beneficially owned 8,747,733 shares of Arteris common stock indirectly attributed to Janac. Separate holding entries show an additional 196,729 shares held directly and 56,252 shares held through the Charles and Lydia Janac Trust.
Arteris, Inc. major holder Bayview Legacy, LLC reported selling common stock in multiple open-market transactions. On July 1, 2026, Bayview executed four sales totaling 181,338 shares of Arteris common stock at weighted average prices between $44.0606 and $47.0752.
The trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by K. Charles Janac, who manages Bayview Legacy, LLC and is deemed to have voting and dispositive power over the shares.
Arteris, Inc. director Saiyed Atiq Raza reported significant insider sales of Arteris (AIP) common stock. On 2026-07-01, a revocable trust for which he serves as trustee sold an aggregate of 70,000 shares in multiple open-market transactions at weighted-average prices including $47.1004, $44.9884, $43.9796 and $46.1987 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the sales, the trust held 119,041 shares of common stock, and Raza also held 4,703 shares directly.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported an open-market sale of 39,541 shares of Common Stock at a price of $43.15 per share on June 16, 2026. This represents a partial reduction of his direct holdings rather than a full exit.
After the transaction, Moll directly holds 227,296 shares of Arteris common stock. A footnote explains that this total includes 1,307 shares acquired on May 21, 2026 through the company’s Employee Stock Purchase Plan, reflecting ongoing participation in an employee equity program even alongside the reported sale.
Arteris, Inc. President and CEO K. Charles Janac reported indirect open-market sales of a total of 70,000 shares of common stock on June 8, 2026. The shares were sold by Bayview Legacy, LLC in two transactions at weighted average prices of $35.1596 and $34.7417, in multiple trades within disclosed price ranges. A footnote states these sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025. Following the transactions, Bayview Legacy, LLC held 8,929,071 shares indirectly, while Janac also held 196,729 shares directly and 56,252 shares through the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of 70,000 shares of AIP common stock. The sales occurred on June 8, 2026 in two tranches at weighted average prices of $34.7417 and $35.1596 per share.
The filing states that these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. All holdings are reported as indirect, through Bayview Legacy, LLC, which is controlled by K. Charles Janac as manager.
Arteris, Inc. director Antonio J. Viana reported indirect sales and gifts of Common Stock. On June 4, 2026, the Viana Family Trust, for which he is trustee, executed open-market sales totaling 20,839 shares of Arteris Common Stock in three blocks: 8,939 shares at a weighted average price of $37.089, 7,000 shares at $36.5082, and 4,900 shares at $35.4661, under a Rule 10b5-1 trading plan adopted on June 10, 2025. The filing also reports bona fide gifts totaling 41,678 shares, split between indirect trust holdings and his direct holdings, at a reported price of $0. Following these transactions, Viana reports 64,620 shares held indirectly through the Viana Family Trust and 4,704 shares held directly.
Arteris, Inc. director Joachim Kunkel received an equity grant of 4,703 shares of common stock in the form of restricted stock units (RSUs) as board compensation. The award carried no cash exercise price and increased his directly held position to 74,330 shares.
The 4,703 RSUs each represent a contingent right to one share of common stock and will vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, as long as he continues serving on the board. The grant was based on the average trading price of Arteris stock of $31.89 over the April 21, 2026 to June 2, 2026 period, and Kunkel elected to defer receipt of the shares.
Viana Antonio J reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Antonio J. Viana reported an equity grant of 4,703 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the grant date or immediately before the next annual stockholder meeting, conditioned on his continued board service.
The grant was made on June 2, 2026, based on an average trading price of $31.89 for Arteris stock from April 21, 2026 through June 2, 2026. Following the grant, Viana holds 25,543 shares directly, including these RSUs, and 64,620 shares indirectly through the Viana Family Trust.
Munce Claudia F. reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Claudia F. Munce received an equity grant of 4,703 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, if she continues serving on the board. The grant value was based on the average trading price of $31.89 over the period from April 21, 2026 through June 2, 2026. Following this award, she holds a total of 106,414 common shares directly, and has elected to defer receipt of the shares underlying this RSU grant.
Chitkara Raman reported acquisition or exercise transactions in this Form 4 filing.
Arteris director Raman Chitkara reported an equity award of 4,703 shares of common stock in the form of restricted stock units (RSUs). The RSUs were granted at no cash cost and will vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, contingent on continued Board service. Following this award, Chitkara directly holds 147,570 shares, and has elected to defer receipt of the underlying shares once the RSUs vest.
Cantwell Wayne C reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Wayne C. Cantwell reported a compensation-related equity grant in common stock. He received 7,839 restricted stock units (RSUs), each representing one share of Arteris common stock. The RSUs vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, subject to his continued board service.
After this grant, Cantwell holds 42,571 shares directly. He also has indirect holdings of 189,698 shares through The Cantwell Living Trust, where he serves as trustee, and 38,761 shares through the Decathlon Capital Management 401K Plan FBO Wayne Cantwell. The grant was based on an average Arteris trading price of $31.89 over the period from April 21, 2026 through June 2, 2026, and the RSUs have no expiration date.
Arteris, Inc. director Saiyed Atiq Raza, through a revocable trust for which he serves as trustee, reported multiple stock transactions in the company’s common shares. On June 3, 2026, the trust sold a total of 20,839 shares in open‑market trades at weighted average prices of $37.1294, $38.4583 and $37.6541 per share, under a pre‑arranged Rule 10b5‑1 trading plan.
The filing also shows bona fide gifts totaling 41,678 shares and a separate grant of 4,703 restricted stock units on June 2, 2026, which vest on the earlier of the first anniversary of the grant or the next annual stockholder meeting. Following these moves, the trust holds 160,839 shares and Raza’s direct holdings consist of 4,703 RSUs.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported option exercises and related share sales in Common Stock. On June 1, 2026, he sold 11,504 shares at a weighted average price of $35.9848 and 998 shares at a weighted average price of $36.3895 in open-market transactions, totaling 12,502 shares sold.
These sales were made pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026. On the same date, he exercised options for 4,000 shares at an exercise price of $0.5600 and 2,500 shares at an exercise price of $9.2800, acquiring 6,500 shares through derivative exercises.
Following the transactions, Alpern held 80,384 to 92,886 shares of Common Stock directly, depending on the specific line item, and retained 61,000 incentive stock options and 27,500 non-qualified stock options with expiration dates in 2029 and 2035, respectively.
Arteris, Inc. director Saiyed Atiq Raza reported open‑market sales of Arteris common stock made through a family trust under a pre‑arranged Rule 10b5‑1 trading plan. On June 1, 2026, the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust sold 70,000 shares in two transactions at weighted average prices of about $35.99 and $36.45 per share.
These transactions were executed in multiple trades within stated price ranges, and the filing notes that detailed trade breakdowns are available on request. After the reported activity, Raza also shows a separate direct holding of 20,839 Arteris shares.
Arteris, Inc. VP and Chief Financial Officer Nicholas B. Hawkins reported an open-market sale of 3,000 shares of common stock. The shares were sold at an average price of $37.7514 per share. After this transaction, he directly holds 108,549 shares of Arteris common stock.
A related footnote notes that this post-transaction amount includes 949 shares of common stock acquired on May 21, 2026 under the company’s Employee Stock Purchase Plan, highlighting ongoing participation in the issuer’s equity programs alongside the reported sale.
Arteris, Inc. director Wayne C. Cantwell reported an open-market sale of Common Stock through The Cantwell Living Trust on May 26, 2026. The trust sold 38,500 shares at a weighted average price of $37.2251 per share, in multiple trades between $36.79 and $37.55.
After the sale, The Cantwell Living Trust held 189,698 Arteris shares. Separate holding entries show Cantwell with 34,732 shares held directly and 38,761 shares held indirectly through the Decathlon Capital Management 401K Plan FBO Wayne Cantwell.
Arteris, Inc. director, President and CEO K. Charles Janac reported an insider transaction involving a bona fide gift of common stock by an entity he manages. Bayview Legacy, LLC, for which he serves as manager, made a gift transfer of 50,000 shares of Common Stock at a stated price of $0.00 per share. After this gift, Bayview Legacy, LLC is shown as beneficially owning 8,999,071 shares of Common Stock, over which Janac is deemed to have voting and dispositive power.
The filing also lists additional holdings as of the same date: 196,729 shares of Common Stock held directly by Janac and 56,252 shares held indirectly through the Charles and Lydia Janac Trust, for which he serves as trustee. The reported transaction is a non-market, non-cash gift rather than an open-market purchase or sale, so it primarily reflects personal or estate-planning activity rather than a change in market view.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported a bona fide gift of 50,000 shares of Common Stock on May 18, 2026 at a stated price of $0.00 per share. This is a non-market transfer classified as a gift rather than a sale.
After the transaction, Bayview Legacy, LLC indirectly holds 8,999,071 Arteris shares. Footnotes state that K. Charles Janac controls Bayview Legacy, LLC as its manager and is deemed to have voting and dispositive power over these shares.
Arteris, Inc. VP and Chief Financial Officer Nicholas B. Hawkins reported an exercise-and-sell sequence in company stock. On May 15, 2026, he exercised stock options covering 213,021 shares of common stock at exercise prices of $0.56 and $9.28 per share.
On the same date, he sold 221,035 shares of common stock in open-market transactions at weighted average prices ranging from about $32.18 to $34.65 per share, according to the footnotes. After these trades, he continues to hold more than 100,000 shares directly.
Arteris, Inc. director Antonio J. Viana reported open-market sales of a total of 40,000 shares of common stock, primarily through the Viana Family Trust. The trust sold 15,538 shares at a weighted average price of $34.0595, 4,462 shares at $35.3534, and 20,000 shares at $38.00.
Following these transactions, the Viana Family Trust held 64,620 shares indirectly, while Viana also held 20,840 shares directly. The filing states that the sales were made under a Rule 10b5-1 trading plan adopted on June 10, 2025, and notes that some shares were sold in multiple trades at prices ranging from $34.00 to $35.43.
Arteris, Inc. director, President and CEO K. Charles Janac reported an indirect open-market sale of 70,000 shares of common stock at a weighted average price of $31.1998 per share through Bayview Legacy, LLC. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025.
Following the sale, Bayview Legacy, LLC held 9,049,071 shares of Arteris common stock. Janac also reported ownership of 196,729 shares held directly and 56,252 shares held indirectly through the Charles and Lydia Janac Trust, for which he serves as trustee.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported an open-market sale of 70,000 shares of common stock on May 8, 2026 at a weighted average price of $31.1998 per share. The trades occurred at prices ranging from $29.19 to $32.07 per share.
After this transaction, Bayview Legacy, LLC held 9,049,071 shares of Arteris common stock indirectly. The sale was executed under a Rule 10b5-1 trading plan adopted by K. Charles Janac, who manages Bayview Legacy, LLC and is deemed to have voting and dispositive power over these shares.
Arteris, Inc. director Antonio J. Viana reported an open-market sale of common stock by the Viana Family Trust. The trust sold 20,000 shares at a weighted average price of $30.0732 per share and now holds 104,620 shares indirectly. Separately, Viana holds 20,840 shares directly. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2025.
Arteris, Inc. director Raman Chitkara sold 5,000 shares of Common Stock in an open-market transaction. The shares were sold on May 5, 2026 at a weighted average price of $30.0536 per share under a pre-arranged Rule 10b5-1 trading plan. After this sale, Chitkara directly holds 142,867 shares of Arteris common stock.
Arteris, Inc. director Saiyed Atiq Raza reported an open‑market sale of 90,000 shares of Common Stock for a weighted average price of $28.713 per share. The sale was executed on May 1, 2026 under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025.
The sold shares are held indirectly through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, where Raza serves as trustee, and this trust held 210,000 shares after the transaction. Separately, Raza directly held 20,839 shares of Arteris common stock following the reported transactions.
Arteris, Inc. director Chitkara Raman sold 5,000 shares of Common Stock in an open-market transaction. The sale occurred on April 24, 2026 at a weighted average price of $25.0579 per share, with individual trades between $25.00 and $25.25.
The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. Following this sale, Raman directly holds 147,867 shares of Arteris common stock.
Arteris, Inc. director Antonio J. Viana, through the Viana Family Trust, sold 20,000 shares of Arteris common stock in an open-market transaction at a weighted average price of $26.1117 per share. After the sale, the trust held 124,620 shares indirectly, and Viana held 20,840 shares directly. The sale was executed under a Rule 10b5-1 trading plan adopted on June 10, 2025.
Arteris, Inc. director Saiyed Atiq Raza, through the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust, reported open‑market sales of a total of 90,000 shares of Arteris common stock at weighted average prices around $22 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions, the trust holds 300,000 shares indirectly, and Raza also holds 20,839 shares directly.
Arteris, Inc. director Antonio J. Viana reported an open‑market sale of common stock through the Viana Family Trust. On April 17, 2026, the trust sold 20,000 shares at a weighted average price of $22.1084 per share under a pre‑arranged Rule 10b5-1 trading plan adopted on June 10, 2025. After this sale, the trust held 144,620 shares of Arteris common stock, while Viana also directly held 20,840 shares, indicating he retains a substantial equity position.